Cargando…

Prophylactic Administration of Surfactant in Extremely Premature Infants

Objective. To investigate whether prophylactic surfactant administration is superior over selective treatment in preterm infants with respiratory distress syndrome (RDS). Methods. In our retrospective analysis, we compared premature infants (23 + 0 to 26 + 6 weeks) receiving 200 mg/kg surfactant (cu...

Descripción completa

Detalles Bibliográficos
Autores principales: Koch, Lutz, Frommhold, David, Beedgen, Bernd, Ruef, Peter, Poeschl, Johannes
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2951078/
https://www.ncbi.nlm.nih.gov/pubmed/20948885
http://dx.doi.org/10.1155/2010/235894
_version_ 1782187682030419968
author Koch, Lutz
Frommhold, David
Beedgen, Bernd
Ruef, Peter
Poeschl, Johannes
author_facet Koch, Lutz
Frommhold, David
Beedgen, Bernd
Ruef, Peter
Poeschl, Johannes
author_sort Koch, Lutz
collection PubMed
description Objective. To investigate whether prophylactic surfactant administration is superior over selective treatment in preterm infants with respiratory distress syndrome (RDS). Methods. In our retrospective analysis, we compared premature infants (23 + 0 to 26 + 6 weeks) receiving 200 mg/kg surfactant (curosurf(®)) within five minutes after birth (prophylactic group, N = 31) with those infants who received surfactant therapy for established RDS (selective group, N = 34). Results. Prophylactic therapy significantly decreased the need for mechanical ventilation (74 hours per patient versus 171 hours per patient, resp.). We observed a reduced incidence of interstitial emphysema (0% versus 9%, resp.), pneumothoraces (3% versus 9%, resp.), chronic lung disease (26% versus 38%, resp.), and surfactant doses per patient (1.3 versus 1.8, resp.), although those variables did not reach significance. Conclusion. We conclude that infants under 27 weeks' gestation profit from prophylactic surfactant administration by reducing the time of mechanical ventilation. This in turn could contribute to reduce the risk for mechanical ventilation associated complications, without any detrimental short-term side effects.
format Text
id pubmed-2951078
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-29510782010-10-14 Prophylactic Administration of Surfactant in Extremely Premature Infants Koch, Lutz Frommhold, David Beedgen, Bernd Ruef, Peter Poeschl, Johannes Crit Care Res Pract Clinical Study Objective. To investigate whether prophylactic surfactant administration is superior over selective treatment in preterm infants with respiratory distress syndrome (RDS). Methods. In our retrospective analysis, we compared premature infants (23 + 0 to 26 + 6 weeks) receiving 200 mg/kg surfactant (curosurf(®)) within five minutes after birth (prophylactic group, N = 31) with those infants who received surfactant therapy for established RDS (selective group, N = 34). Results. Prophylactic therapy significantly decreased the need for mechanical ventilation (74 hours per patient versus 171 hours per patient, resp.). We observed a reduced incidence of interstitial emphysema (0% versus 9%, resp.), pneumothoraces (3% versus 9%, resp.), chronic lung disease (26% versus 38%, resp.), and surfactant doses per patient (1.3 versus 1.8, resp.), although those variables did not reach significance. Conclusion. We conclude that infants under 27 weeks' gestation profit from prophylactic surfactant administration by reducing the time of mechanical ventilation. This in turn could contribute to reduce the risk for mechanical ventilation associated complications, without any detrimental short-term side effects. Hindawi Publishing Corporation 2010 2010-06-07 /pmc/articles/PMC2951078/ /pubmed/20948885 http://dx.doi.org/10.1155/2010/235894 Text en Copyright © 2010 Lutz Koch et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Koch, Lutz
Frommhold, David
Beedgen, Bernd
Ruef, Peter
Poeschl, Johannes
Prophylactic Administration of Surfactant in Extremely Premature Infants
title Prophylactic Administration of Surfactant in Extremely Premature Infants
title_full Prophylactic Administration of Surfactant in Extremely Premature Infants
title_fullStr Prophylactic Administration of Surfactant in Extremely Premature Infants
title_full_unstemmed Prophylactic Administration of Surfactant in Extremely Premature Infants
title_short Prophylactic Administration of Surfactant in Extremely Premature Infants
title_sort prophylactic administration of surfactant in extremely premature infants
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2951078/
https://www.ncbi.nlm.nih.gov/pubmed/20948885
http://dx.doi.org/10.1155/2010/235894
work_keys_str_mv AT kochlutz prophylacticadministrationofsurfactantinextremelyprematureinfants
AT frommholddavid prophylacticadministrationofsurfactantinextremelyprematureinfants
AT beedgenbernd prophylacticadministrationofsurfactantinextremelyprematureinfants
AT ruefpeter prophylacticadministrationofsurfactantinextremelyprematureinfants
AT poeschljohannes prophylacticadministrationofsurfactantinextremelyprematureinfants